Some of the positive decisions made by Cocrystal Pharma Inc (OTCBB:COCP) have paid off in a great way. Recently, the company appointed Jeffrey Meckler as the interim CEO after performing well in the last financial year. After the announcement, the stock price of COCP surged significantly. It posted gains of more than 4% to close at $1.18. In last trading session, the stock price of COCP declined 0.85% to close at $1.17 with share volume of 578,047 compared to the average volume of 1.45 million.
The recent selection of Meckler came as a surprise to several people. It was not a planned move, but a brave decision taken a time when anything could have gone wrong. The full-time CEO, Dr. Gary Wilcox has not been feeling well for the past few months. The poor health was not permitting him to continue working for full time with Cocrystal. After he informed that he wouldn’t be able to continue, the Board of Directors informed Meckler’s name as the new interim CEO.
Dr. Wilcox has reigned from full time Chief Executive Position. However, he would continue providing his valuable advice to the company as the Vice Chairman of Cocrystal’s Board. Before getting appointed as the interim Chief Executive, Meckler served as one of the key directors of Cocrystal. The last report suggested that he will also continue to be the director of the company. The Board will be headed by Dr. Raymond F. Schinazi. He will act as the Chairman of the Board.
Meckler has an extensive experience of 25 years in the field of life science. He was associated with multiple companies such as Pfizer Inc. (NYSE:PFE) where he spent more than 17 years and took diverse leadership roles. The new role offers new opportunity for Meckler to show his skills in supporting the growth of the company.